Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pulmonary vein ostial myocardium refers to the specialized sleeves of cardiac muscle that extend from the left atrium into the proximal segments of the pulmonary veins, especially at their ostia (junctions with the left atrium)[1]. These myocardial sleeves exhibit active, sphincter-like contractility that helps regulate blood flow into the left atrium and protects the pulmonary vascular bed from sudden increases in left atrial pressure[1]. They also display unique electrophysiological properties and serve as a major source of focal electrical activity that can initiate atrial fibrillation (AF), making the pulmonary vein ostia critical anatomical foci in AF pathophysiology[3][1]. Loss of contractile competence and pathological remodeling (fibrosis, hypertrophy, altered ion channel expression) of the pulmonary vein ostial myocardium is associated with the progression of atrial myopathy and worsening atrial fibrillation[1]. As a whole, the pulmonary vein ostial myocardium is an anatomical structure but is not a receptor, molecule, or classical druggable target; it is instead the source tissue ablated in catheter-based AF therapies where the intended mechanism is the electrical isolation of arrhythmogenic myocardial foci[6][3][1]. - The "pulmonary vein ostial myocardium" is not a molecular entity such as a receptor, enzyme, channel, or transporter, but rather an anatomical tissue layer with unique contractile and electrophysiological functions. - It is often described in the context of atrial fibrillation because of its role as the trigger zone for arrhythmias and as a target for non-pharmacological ablation therapies. - No known small molecule drugs interact directly with this structure; interventions are procedural (ablation, surgical isolation)[6]. - The term is sometimes used inconsistently in literature; it is anatomically accurate but does not correspond to a single, well-defined protein, receptor, or molecular target typically found in pharmacological databases.
For ablation therapies: electrical isolation via catheter ablation eliminates arrhythmogenic impulses
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pulmonary vein ostial myocardium.